發(fā)布時間：2018-01-30 00:09

  本文關(guān)鍵詞： 原發(fā)性血小板增多癥 預后因素 生存分析　出處：《中國實驗血液學雜志》2017年02期 　論文類型：期刊論文

【摘要】：目的:探討原發(fā)性血小板增多癥(ET)患者的預后及生存狀態(tài),分析影響該疾病生存的預后因素,為臨床診治和判定預后提供依據(jù)。方法:對2002年12月至2013年12月在中山大學附屬第五醫(yī)院和中山市人民醫(yī)院住院確診的ET患者進行統(tǒng)計分析,總結(jié)其臨床特點并進行生存曲線分析及多因素分析,尋找該疾病的生存特點及影響預后的危險因素。結(jié)果:118例ET患者的生存情況為1年生存率95.5%,3年生存率92.6%,5年生存率89%,10年生存率81.6%。Kaplan-Meier法生存分析提示年齡≥60歲、有心血管危險因素、既往有血栓或出血病史、貧血(血紅蛋白120 g/L)、血小板計數(shù)升高(≥1 000×109/L)、疾病危險分級、高危組中使用羥基脲或/和高三尖杉酯堿對生存率的影響有統(tǒng)計學意義(P0.05)。COX回歸分析顯示,未發(fā)現(xiàn)影響生存率的獨立危險因素。結(jié)論:ET患者的生存率高,生存時間長,轉(zhuǎn)化為骨髓纖維化和白血病的風險低,年齡≥60歲、有心血管疾病危險因素、既往有血栓或出血病史、貧血、血小板計數(shù)升高是影響預后的危險因素,在高危組中使用羥基脲或/和高三尖杉酯堿能改善預后
[Abstract]:Objective: to investigate the prognosis and survival status of patients with idiopathic thrombocytopenia (et) and to analyze the prognostic factors affecting the survival of the disease. Methods: to provide evidence for clinical diagnosis, treatment and prognosis. From December 2002 to December 2013, the et patients who were hospitalized in 5th affiliated Hospital of Sun Yat-sen University and Zhongshan people's Hospital were statistically analyzed. The clinical characteristics were summarized and survival curve analysis and multivariate analysis were carried out. Results the survival rate of one year survival rate was 95.50.The 3-year survival rate was 92.6 and the 5-year survival rate was 89%. The survival rate of 10 years was 81.6%. Kaplan-Meier survival analysis showed that the age 鈮，

本文編號：1474732